← Leaderboards
Ole Isacson
Mclean Hospital
$16,866,444
Attributed
$26,810,167
Total exposure
35
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$44,960,542 · 37
By mechanism
P50$19,086,515 · 4
U01$9,168,144 · 1
R01$6,447,797 · 3
RC2$3,779,091 · 1
U24$2,550,424 · 3
RF1$2,284,296 · 1
Top collaborators
- Penelope Jane Hallett13 shared
- James M Schumacher7 shared
- Michelle L Hastings5 shared
- Oliver Cooper4 shared
- Anna Charlotta Teresia Magnuson Osborn3 shared
Most similar at Mclean Hospital
Same institution · by research overlap
- Penelope Jane Hallett$5,641,169
- Sabina Berretta$31,866,827
Others in their field
Top investigators on “Parkinson'S Disease”
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$92,426,001
- David M Anderson · University Of Washington$40,483,703
- Daniel M Corcos · Northwestern University$37,632,589
- Joel Synes Perlmutter · Washington University$37,192,743
- Jerrold L Vitek · University Of Minnesota$35,135,315
- Joseph B Martin · Harvard University (Medical School)$26,652,023
Research focus
Parkinson'S DiseaseDopamineResearch PersonnelParkinson DiseaseNonhuman Therapy EvaluationCellsResourcesInduced Pluripotent Stem CellNeuroprotectantsSourceGrantUnited States National Institutes Of HealthCell LineNeuronsDisease /Disorder ModelDopaminergic NeuronNerve DegenerationMagnetic Resonance ImagingFundingPositron Emission TomographyBrainCore FacilitySynapsesGenetic
Grant awards (93)
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,958,850
U01 · FY2024 · NS
ApoE, lipid and immune mechanisms of human neurons and glia$2,284,296
RF1 · FY2023 · AG · contact PI
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,961,294
U01 · FY2023 · NS
Parkinsons disease scalable iPSC autologous cell therapy$164,000
U01 · FY2023 · NS
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,640,000
U01 · FY2022 · NS
Prevention of complement and immune-mediated Lewy body dementia$563,846
R01 · FY2022 · AG · contact PI
Parkinsons disease scalable iPSC autologous cell therapy$164,000
U01 · FY2022 · NS
Parkinsons disease scalable iPSC autologous cell therapy$1,640,000
U01 · FY2021 · NS
Prevention of complement and immune-mediated Lewy body dementia$569,300
R01 · FY2021 · AG · contact PI
Parkinsons disease scalable iPSC autologous cell therapy$1,640,000
U01 · FY2020 · NS
Prevention of complement and immune-mediated Lewy body dementia$574,594
R01 · FY2020 · AG · contact PI
Prevention of complement and immune-mediated Lewy body dementia$579,735
R01 · FY2019 · AG · contact PI
Prevention of complement and immune-mediated Lewy body dementia$600,725
R01 · FY2018 · AG · contact PI
Gene signatures linked to the cell biological phenotypes of familial PD$195,525
R21 · FY2014 · NS · contact PI
PD iPS Cell Line Consortium$844,623
U24 · FY2013 · NS · contact PI
Gene signatures linked to the cell biological phenotypes of familial PD$237,000
R21 · FY2013 · NS · contact PI
Adminitrative Core$168,924
U24 · FY2013 · NS · contact PI
Resource Core$168,924
U24 · FY2013 · NS · contact PI
PD iPS Cell Line Consortium$920,681
U24 · FY2012 · NS · contact PI
Adminitrative Core$184,136
U24 · FY2012 · NS · contact PI
Resource Core$184,136
U24 · FY2012 · NS · contact PI
PD iPS Cell Line Consortium$79,000
U24 · FY2012 · NS · contact PI
PD iPS Cell Line Research Consortium$1,814,581
RC2 · FY2010 · NS · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$156,554
P50 · FY2010 · NS · contact PI
PD iPS Cell Line Research Consortium$79,000
RC2 · FY2010 · NS · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$2,078,654
P50 · FY2009 · NS · contact PI
PD iPS Cell Line Research Consortium$1,885,510
RC2 · FY2009 · NS · contact PI
New Approach to PD Neuroprotection using Cell Type Specific Analysis$508,188
P50 · FY2009 · NS · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$131,408
P50 · FY2009 · NS · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$128,976
P50 · FY2009 · NS · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$114,156
P50 · FY2009 · NS · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$98,876
P50 · FY2009 · NS · contact PI
NOVEL THERAPEUTIC APPROACHES FOR PD$12,733
P51 · FY2009 · RR · contact PI
NEURAL TRANSPLANTATION IN NONHUMAN PRIMATE MODELS OF PARKINSON'S DISEASE$12,721
P51 · FY2009 · RR · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$2,016,348
P50 · FY2008 · NS · contact PI
New Approach to PD Neuroprotection using Cell Type Specific Analysis$493,546
P50 · FY2008 · NS · contact PI
THE USE OF EMBRYONIC PRIMATE STEM CELLS IN PARKINSON?S DISEASE MODELS$55,151
P51 · FY2008 · RR · contact PI
NOVEL ANTI-INFLAMMATORY THERAPIES FOR PD$55,151
P51 · FY2008 · RR · contact PI
NOVEL THERAPEUTIC APPROACHES FOR PD$55,151
P51 · FY2008 · RR · contact PI
NOVEL THERAPEUTIC APPROACHES FOR HUNTINGTON?S DISEASE$55,151
P51 · FY2008 · RR · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$2,014,428
P50 · FY2007 · NS · contact PI
New Approach to PD Neuroprotection using Cell Type Specific Analysis$494,016
P50 · FY2007 · NS · contact PI
NOVEL THERAPEUTIC APPROACHES FOR HUNTINGTON?S DISEASE$103,635
P51 · FY2007 · RR · contact PI
NOVEL THERAPEUTIC APPROACHES FOR PD$103,634
P51 · FY2007 · RR · contact PI
NOVEL ANTI-INFLAMMATORY THERAPIES FOR PD$103,634
P51 · FY2007 · RR · contact PI
THE USE OF EMBRYONIC PRIMATE STEM CELLS IN PARKINSON?S DISEASE MODELS$103,634
P51 · FY2007 · RR · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$2,015,705
P50 · FY2006 · NS · contact PI
New Approach to PD Neuroprotection using Cell Type Specific Analysis$387,153
P50 · FY2006 · NS · contact PI
THE USE OF EMBRYONIC PRIMATE STEM CELLS IN PARKINSON?S DISEASE MODELS$34,958
P51 · FY2006 · RR · contact PI
NOVEL THERAPEUTIC APPROACHES FOR PD$34,958
P51 · FY2006 · RR · contact PI
NOVEL ANTI-INFLAMMATORY THERAPIES FOR PD$34,958
P51 · FY2006 · RR · contact PI
ROLE OF NOCICEPTIN/ORPHANIN FQ IN REGULATION OF MOTOR BEHAVIOR & INDUCTION OF PD$34,958
P51 · FY2006 · RR · contact PI
Novel Therapeutic Approaches for Parkinson's Disease$2,025,533
P50 · FY2005 · NS
New Approach to PD Neuroprotection using Cell Type Specific Analysis$375,879
P50 · FY2005 · NS
NOVEL ANTI-INFLAMMATORY THERAPIES FOR PD$33,521
P51 · FY2005 · RR
TRANSGENIC XENOGRAFTS FOR HD$33,521
P51 · FY2005 · RR
NOVEL THERAPEUTIC APPROACHES FOR PD$33,521
P51 · FY2005 · RR
THE USE OF EMBRYONIC PRIMATE STEM CELLS IN PARKINSON'S DISEASE MODELS$33,521
P51 · FY2005 · RR
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD$525,515
R01 · FY2004 · NS
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$391,551
P50 · FY2004 · NS
EMBRYONIC PRIMATE STEM CELL IN PARKINSON'S DISEASE MODEL$35,475
P51 · FY2004 · RR
NOVEL ANTI-INFLAMMATORY THERAPIES FOR PD$35,475
P51 · FY2004 · RR
NOVEL THERAPEUTIC APPROACHES FOR PD$35,475
P51 · FY2004 · RR
TRANSGENIC XENOGRAFTS FOR HUNTINGTON'S DISEASE$35,475
P51 · FY2004 · RR
BRAIN REPAIR STUDIES OF PD MODELS BY NEUROSURGICAL, PET AND MRI/MRS METHODS$35,475
P51 · FY2004 · RR
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$1,341,350
P50 · FY2003 · NS
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD$510,208
R01 · FY2003 · NS
NOVEL THERAPEUTIC APPROACHES FOR PD$24,966
P51 · FY2003 · RR
TRANSGENIC XENOGRAFTS FOR HUNTINGTON'S DISEASE$24,966
P51 · FY2003 · RR
BRAIN REPAIR STUDIES OF PD MODELS BY NEUROSURGICAL, PET AND MRI/MRS METHODS$24,966
P51 · FY2003 · RR
NOVEL ANTI-INFLAMMATORY THERAPIES FOR PD$24,966
P51 · FY2003 · RR
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$1,312,315
P50 · FY2002 · NS
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD$495,344
R01 · FY2002 · NS
TRANSGENIC XENOTRANSPLANTS FOR HUNTINGTON'S DISEASE$355,500
R01 · FY2002 · NS
Gene Regulation/Stem Cell Transplantation: Parkinson's$262,675
P50 · FY2002 · NS
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$100,000
P50 · FY2002 · NS
NOVEL PROTECTIVE NEUROPHILINS IN IDIOPATHIC PARKINSON'S DISEASE$0
P50 · FY2002 · NS
NOVEL PROTECTIVE NEUROPHILINS IN IDIOPATHIC PARKINSON'S DISEASE$0
P50 · FY2002 · NS
EDUCATION$0
P50 · FY2002 · NS
EDUCATION$0
P50 · FY2002 · NS
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$983,923
P50 · FY2001 · NS
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD$480,916
R01 · FY2001 · NS
TRANSGENIC XENOTRANSPLANTS FOR HUNTINGTON'S DISEASE$355,500
R01 · FY2001 · NS
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$100,000
P50 · FY2001 · NS
EDUCATION$53,566
P50 · FY2001 · NS
NOVEL PROTECTIVE NEUROPHILINS IN IDIOPATHIC PARKINSON'S DISEASE$53,566
P50 · FY2001 · NS
EDUCATION$0
P50 · FY2001 · NS
NOVEL PROTECTIVE NEUROPHILINS IN IDIOPATHIC PARKINSON'S DISEASE$0
P50 · FY2001 · NS
NOVEL THERAPEUTIC APPROACHES FOR PARKINSON'S DISEASE$1,033,619
P50 · FY2000 · NS
ANTI-INFLAMMATORY THERAPIES NEUROTOXICALLY INDUCED PD$481,114
R01 · FY2000 · NS
TRANSGENIC XENOTRANSPLANTS FOR HUNTINGTON'S DISEASE$355,500
R01 · FY2000 · NS
EDUCATION$207,265
P50 · FY2000 · NS
NOVEL PROTECTIVE NEUROPHILINS IN IDIOPATHIC PARKINSON'S DISEASE$207,265
P50 · FY2000 · NS